Advances in Cancer Immunotherapy™:
A Focus on Immune Checkpoint Inhibitors

This program has already taken place:
Saturday, April 23, 2022
8 a.m.-12 p.m. EDT
Hosted on Zoom Webinar

Join SITC and a panel of experts for an afternoon of in-depth education on recent updates in the use of immune checkpoint inhibitors clinically.

Organizers:

Tina Cascone, MD, PhD – The University of Texas MD Anderson Cancer Center
David E. Gerber, MD – Harold C. Simmons Comprehensive Cancer Center
Jamie S. Lin, MD, FASN – The University of Texas MD Anderson Cancer Center

Program Agenda

8–8:20 a.m.	MOA of checkpoint inhibition Marina Chiara Garassino, MD – The University of Chicago
8:20–8:40 a.m.	Patient Selection, Efficacy and Biomarkers Natalie Vokes, MD – The University of Texas MD Anderson Cancer Center
8:40–9 a.m.	Patient Selection Based on Safety Concerns Jarushka Naidoo, MBBCH, MHS – Beaumont RCSI Cancer Centre Dublin
9–9:20 a.m.	Monitoring Diane Tseng, MD, PhD – University of Washington School of Medicine, Fred Hutchinson Cancer Research Center
9:20–9:30 a.m.	Break
9:30–10:30 a.m.	Specialists on diagnosis and treatment Pulmonologist: Vickie Shannon, MD – The University of Texas MD Anderson Cancer Center Rheumatologist: Bonnie Bermas, MD – UT Southwestern Medical Center Endocrinologist: Sadia Ali, MD – UT Southwestern Medical Center
10:30–10:50 a.m.	Cancer Immunotherapy in Practice Nikhil I. Khushalani, MD – Moffitt Cancer Center
10:50-11 a.m.	Break
11 a.m.-12 p.m.	Faculty Case Study Panel Sadia Ali, MD – UT Southwestern Medical Center Bonnie Bermas, MD – UT Southwestern Medical Center Marina Chiara Garassino, MD – The University of Chicago Nikhil I. Khushalani, MD – Moffitt Cancer Center Jamie S. Lin – The University of Texas MD Anderson Cancer Center Jarushka Naidoo, MBBCH, MHS – Beaumont RCSI Cancer Centre Dublin Vickie Shannon, MD – The University of Texas MD Anderson Cancer Center Diane Tseng, MD, PhD – University of Washington School of Medicine, Fred Hutchinson Cancer Research Center Natalie Vokes, MD – The University of Texas MD Anderson Cancer Center

Program Learning Objectives

Describe the mechanisms of immune checkpoint inhibitors.
Summarize recent updates in the use of immune checkpoint inhibitors clinically and toxicity management for key disease states.
Outline common toxicities with immune checkpoint inhibitors and their management.

Target Audience
The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute of Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

Avoid Fraudulent ACI Registration Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org.

If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email education@sitcancer.org.

The ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Postgraduate Institute for Medicine SITC Logo

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc. (as of 1/19/2022)

The 2021-2022 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Association of Community Cancer Centers, Advances Practitioner Society for Hematology and Oncology, and Hematology/Oncology Pharmacy Association. This program is provided in collaboration with the American Academy of Emergency Medicine.